Zacks Investment Research downgraded Emergent Biosolutions Inc (NYSE:EBS) to Strong Sell in a report released today.
- Updated: October 5, 2016
Yesterday Emergent Biosolutions Inc (NYSE:EBS) traded 2.65% higher at $32.35. EBS’s 50-day average is $27.88 and its two hundred day average is $34.10. With the last stock price close down -5.03% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 348,926 shares of EBS changing hands under the typical 545,260
Zacks Investment Research has downgraded Emergent Biosolutions Inc (NYSE:EBS) to Strong Sell in a report released on 10/05/2016.
Previously on Tuesday June 28, 2016, Singular Research reported on Emergent Biosolutions Inc (NYSE:EBS) reduced the target price from $44.00 to $40.00. At the time, this indicated a possible upside of 0.47%.
Recent Performance Chart
Emergent Biosolutions Inc has PE ratio of 23.17 with a one year low of $26.12 and a one year high of $44.38 and has a total market value of $0.
A total of 5 analysts have released a report on Emergent Biosolutions Inc. Two brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $42.80.
General Company Details For Emergent Biosolutions Inc (NYSE:EBS)
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.